Abzena

Abzena is a biologics research partner providing integrated end-to-end solutions for the discovery, development and manufacturing of biopharmaceuticals. The company offers antibody and protein engineering, including humanization, deimmunization, affinity maturation and reformatting, as well as antibody drug conjugate design and conjugation technologies. It supplies discovery and development capabilities such as phage display, Hybridoma sequencing, developability and immunogenicity assessments, bespoke bioassays and analytics, and in vitro safety evaluations. Abzena also provides mammalian cell line development, process and analytical development, and manufacturing services for biopharmaceuticals, with capabilities spanning production, bioanalytics, and assay development. Its integrated ecosystem encompasses cell line platforms, rapid analytics, immunogenicity testing, and bioconjugation workflows to de-risk and accelerate drug development from discovery through mid-phase development and toward clinical readiness, serving biopharma and biotech clients with scientifically robust, regulatory-compliant solutions that aim to shorten time to clinic.